AAAAAA

   
Results: 1-25 | 26-36
Results: 1-25/36
CHEMOTHERAPY IMMEDIATELY FOLLOWING AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH ADVANCED BREAST-CANCER
Authors: RAHMAN Z KAVANAGH J CHAMPLIN R GILES R HANANIA E FU SQ ZU ZF MEHRA R HOLMES F KUDELKA A CLAXTON D VERSCHRAEGEN C GAJEWSKI J ANDREEFF M HEIMFELD S BERENSON R ELLERSON D CALVERT L MECHETNER E HOLZMAYER T DAYNE A HAMER J BACHIER C OSTROVE J PRZEPIORKA D BURTNESS B COTE R BAST R HORTOBAGYI G DEISSEROTH A
Citation: Z. Rahman et al., CHEMOTHERAPY IMMEDIATELY FOLLOWING AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH ADVANCED BREAST-CANCER, Clinical cancer research, 4(11), 1998, pp. 2717-2721
CLINICAL COURSE OF BREAST-CANCER PATIENTS WITH METASTASES CONFINED TOTHE LUNGS TREATED WITH CHEMOTHERAPY
Authors: DIAZCANTON EA VALERO V RAHMAN Z RODRIGUEZMONGE E FRYE D SMITH T BUZDAR AU HORTOBAGYI GN
Citation: Ea. Diazcanton et al., CLINICAL COURSE OF BREAST-CANCER PATIENTS WITH METASTASES CONFINED TOTHE LUNGS TREATED WITH CHEMOTHERAPY, Annals of oncology, 9(4), 1998, pp. 413-418
ALLOGENEIC PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION FOR POOR-RISK PATIENTS WITH METASTATIC BREAST-CANCER
Authors: UENO NT RONDON G MIRZA NQ GEISLER DK ANDERLINI P GIRALT SA ANDERSSON BS CLAXTON DF GAJEWSKI JL KHOURI IF KORBLING M MEHRA RC PRZEPIORKA D RAHMAN Z SAMUELS BI VANBESIEN K HORTOBAGYI GN CHAMPLIN RE
Citation: Nt. Ueno et al., ALLOGENEIC PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION FOR POOR-RISK PATIENTS WITH METASTATIC BREAST-CANCER, Journal of clinical oncology, 16(3), 1998, pp. 986-993
PATIENT SELECTION IN HIGH-DOSE TRIALS OF BREAST-CANCER - REPLY
Authors: RAHMAN Z BUZDAR A HORTOBAGYI GN
Citation: Z. Rahman et al., PATIENT SELECTION IN HIGH-DOSE TRIALS OF BREAST-CANCER - REPLY, Journal of clinical oncology, 16(3), 1998, pp. 1239-1239
A PHASE-II STUDY OF DOCETAXEL IN PATIENTS WITH PACLITAXEL-RESISTANT METASTATIC BREAST-CANCER
Authors: VALERO V JONES SE VONHOFF DD BOOSER DJ MENNEL RG RAVDIN PM HOLMES FA RAHMAN Z SCHOTTSTAEDT MW ERBAN JK ESPARZAGUERRA L EARHART RH HORTOBAGYI GN BURRIS HA
Citation: V. Valero et al., A PHASE-II STUDY OF DOCETAXEL IN PATIENTS WITH PACLITAXEL-RESISTANT METASTATIC BREAST-CANCER, Journal of clinical oncology, 16(10), 1998, pp. 3362-3368
PRELIMINARY-RESULTS OF A RANDOMIZED TRIAL COMPARING INTENSIVE CHEMOTHERAPY WITH GROWTH-FACTOR (GF) OR PERIPHERAL-BLOOD PROGENITOR (PBPC) CELL MOBILIZATION TO GROWTH-FACTOR ALONE FOR HEMATOPOIETIC RESCUE AFTER HIGH-DOSE CHEMOTHERAPY (HDC)
Authors: GAJEWSKI J RONDON G MIRZA N MEHRA R DONATO M ANDERLINI P KORBLING M THERIALT R KHOURI I GIRALT S BUZDAR A UENO N PRZEPIORKA D ANDERSSON B DURRETT A SALIBA R BRUTON J RAHMAN Z IPPOLITI C HORTABAQYI G RABER M BAST R CHAMPLIN R
Citation: J. Gajewski et al., PRELIMINARY-RESULTS OF A RANDOMIZED TRIAL COMPARING INTENSIVE CHEMOTHERAPY WITH GROWTH-FACTOR (GF) OR PERIPHERAL-BLOOD PROGENITOR (PBPC) CELL MOBILIZATION TO GROWTH-FACTOR ALONE FOR HEMATOPOIETIC RESCUE AFTER HIGH-DOSE CHEMOTHERAPY (HDC), Experimental hematology, 26(8), 1998, pp. 371-371
MORBIDITY OF INTRACRANIAL HEMORRHAGE IN PATIENTS WITH CEREBRAL ARTERIOVENOUS MALFORMATION
Authors: MORGAN M SEKHON L RAHMAN Z DANDIE G
Citation: M. Morgan et al., MORBIDITY OF INTRACRANIAL HEMORRHAGE IN PATIENTS WITH CEREBRAL ARTERIOVENOUS MALFORMATION, Stroke, 29(9), 1998, pp. 2001-2001
A RESULT ON EXPONENTIAL TRACKING ERROR CONVERGENCE AND PERSISTENT EXCITATION
Authors: BAYARD DS SPANOS S RAHMAN Z
Citation: Ds. Bayard et al., A RESULT ON EXPONENTIAL TRACKING ERROR CONVERGENCE AND PERSISTENT EXCITATION, IEEE transactions on automatic control, 43(9), 1998, pp. 1334-1338
COMPARISON BETWEEN EPIDURAL INTRAVENOUS KETAMINE AND SYSTEMIC ANALGESIA FOR POST OPERATIVE PAIN MANAGEMENT
Authors: AZIZ L RAHMAN Z
Citation: L. Aziz et Z. Rahman, COMPARISON BETWEEN EPIDURAL INTRAVENOUS KETAMINE AND SYSTEMIC ANALGESIA FOR POST OPERATIVE PAIN MANAGEMENT, Anesthesia and analgesia, 86(2S), 1998, pp. 257-257
PROSPECTIVE RANDOMIZED TRIAL OF PACLITAXEL ALONE VERSUS 5-FLUOROURACIL DOXORUBICIN/CYCLOPHOSPHAMIDE AS INDUCTION THERAPY IN PATIENTS WITH OPERABLE BREAST-CANCER/
Authors: BUZDAR AU HORTOBAGYI GN ASMAR L THERIAULT RL RAHMAN Z MCNEESE M SINGLETARY S AMES F
Citation: Au. Buzdar et al., PROSPECTIVE RANDOMIZED TRIAL OF PACLITAXEL ALONE VERSUS 5-FLUOROURACIL DOXORUBICIN/CYCLOPHOSPHAMIDE AS INDUCTION THERAPY IN PATIENTS WITH OPERABLE BREAST-CANCER/, Seminars in oncology, 24(5), 1997, pp. 31-34
PROSPECTIVE ASSESSMENT OF CARDIAC TOXICITY DURING A RANDOMIZED PHASE-II TRIAL OF DOXORUBICIN AND PACLITAXEL IN METASTATIC BREAST-CANCER
Authors: HORTOBAGYI GN WILLEY J RAHMAN Z HOLMES FA THERIAULT RL BUZDAR AU
Citation: Gn. Hortobagyi et al., PROSPECTIVE ASSESSMENT OF CARDIAC TOXICITY DURING A RANDOMIZED PHASE-II TRIAL OF DOXORUBICIN AND PACLITAXEL IN METASTATIC BREAST-CANCER, Seminars in oncology, 24(5), 1997, pp. 65-68
PHASE I II STUDY OF DOSE-INTENSE DOXORUBICIN/PACLITAXEL/CYCLOPHOSPHAMIDE WITH PERIPHERAL-BLOOD PROGENITOR CELLS AND CYTOKINE SUPPORT IN PATIENTS WITH METASTATIC BREAST-CANCER/
Authors: RAHMAN Z CHAMPLIN R RONDON G FRYE D VALERO V MEHRA R HORTOBAGYI G
Citation: Z. Rahman et al., PHASE I II STUDY OF DOSE-INTENSE DOXORUBICIN/PACLITAXEL/CYCLOPHOSPHAMIDE WITH PERIPHERAL-BLOOD PROGENITOR CELLS AND CYTOKINE SUPPORT IN PATIENTS WITH METASTATIC BREAST-CANCER/, Seminars in oncology, 24(5), 1997, pp. 77-80
COMBINATION CHEMOTHERAPY WITH PACLITAXEL AND DOXORUBICIN FOR METASTATIC BREAST-CANCER
Authors: HORTOBAGYI GN HOLMES FA THERIAULT RL RAHMAN Z BUZDAR AU
Citation: Gn. Hortobagyi et al., COMBINATION CHEMOTHERAPY WITH PACLITAXEL AND DOXORUBICIN FOR METASTATIC BREAST-CANCER, Seminars in oncology, 24(4), 1997, pp. 13-19
MISSED CURABLE CARCINOMA OF THE PANCREAS PRESENTING AS CHRONIC-PANCREATITIS
Authors: WHARTON SM RAHMAN Z JOHNSON CD
Citation: Sm. Wharton et al., MISSED CURABLE CARCINOMA OF THE PANCREAS PRESENTING AS CHRONIC-PANCREATITIS, Postgraduate medical journal, 73(863), 1997, pp. 577-579
RESULTS OF MDR-1 VECTOR MODIFICATION TRIAL INDICATE THAT GRANULOCYTE MACROPHAGE COLONY-FORMING UNIT CELLS DO NOT CONTRIBUTE TO POSTTRANSPLANT HEMATOPOIETIC RECOVERY FOLLOWING INTENSIVE SYSTEMIC THERAPY (VOL 93, PG 15346, 1996)/
Authors: HANANIA EG GILES RE KAVANAGH J FU SQ ELLERSON D ZU Z WANG T SU Y KUDELKA A RAHMAN Z HOLMES F HORTOBAGYI G CLAXTON D BACHIER C THALL P CHENG S HESTER J OSTROVE JM BIRD RE CHANG A KORBLING M SEONG D COTE R HOLZMAYER T MECHETNER E HEIMFELD S BERENSON R BURTNESS B EDWARDS C BAST B ANDREEFF M CHAMPLIN R DEISSEROTH AB
Citation: Eg. Hanania et al., RESULTS OF MDR-1 VECTOR MODIFICATION TRIAL INDICATE THAT GRANULOCYTE MACROPHAGE COLONY-FORMING UNIT CELLS DO NOT CONTRIBUTE TO POSTTRANSPLANT HEMATOPOIETIC RECOVERY FOLLOWING INTENSIVE SYSTEMIC THERAPY (VOL 93, PG 15346, 1996)/, Proceedings of the National Academy of Sciences of the United Statesof America, 94(10), 1997, pp. 5495-5495
CHEMOTHERAPY-INDUCED NEUTROPENIA AND FEVER IN PATIENTS WITH METASTATIC BREAST-CARCINOMA RECEIVING SALVAGE CHEMOTHERAPY
Authors: RAHMAN Z ESPARZAGUERRA L YAP HY FRASCHINI G BODEY G HORTOBAGYI G
Citation: Z. Rahman et al., CHEMOTHERAPY-INDUCED NEUTROPENIA AND FEVER IN PATIENTS WITH METASTATIC BREAST-CARCINOMA RECEIVING SALVAGE CHEMOTHERAPY, Cancer, 79(6), 1997, pp. 1150-1157
RESULTS OF CD8 DEPLETED ALLOGENEIC PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION (CD8- ALLO-PBSC) FOR CHRONIC MYELOGENOUS LEUKEMIA (CML)
Authors: GIRALT S MIRZA N MEHRA R GAJEWSKI J ANDERSSON B PRZEPIORKA D KHOURI I KORBLING M COHEN A RAHMAN Z VANBESIEN K IPPOLITI C BRUTON J ANDERLINI P UENO N CHAMPLIN R
Citation: S. Giralt et al., RESULTS OF CD8 DEPLETED ALLOGENEIC PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION (CD8- ALLO-PBSC) FOR CHRONIC MYELOGENOUS LEUKEMIA (CML), Blood, 90(10), 1997, pp. 1657-1657
THE HUMAN MULTIPLE-DRUG RESISTANCE GENE (MDR-1) IS USED TO CONFER CHEMOPROTECTION UPON HEMATOPOIETIC PROGENITOR CELLS IN A CLINICAL GENE-THERAPY TRIAL SETTING FOR OVARIAN AND BREAST-CANCER-TREATMENT
Authors: HANANIA EG GILES RE KAVANAGH J ELLERSON D WANG T ZU Z CALVERT L HALEY T HAMER J BERENSON R HEIMFELD S RAHMAN Z CHAMPLIN R DEISSEROTH AB
Citation: Eg. Hanania et al., THE HUMAN MULTIPLE-DRUG RESISTANCE GENE (MDR-1) IS USED TO CONFER CHEMOPROTECTION UPON HEMATOPOIETIC PROGENITOR CELLS IN A CLINICAL GENE-THERAPY TRIAL SETTING FOR OVARIAN AND BREAST-CANCER-TREATMENT, Journal of investigative medicine, 44(3), 1996, pp. 314-314
VIBRATION ISOLATION, SUPPRESSION AND STEERING (VISS)
Authors: WADA BK RAHMAN Z KEDIKIAN R KUO CP
Citation: Bk. Wada et al., VIBRATION ISOLATION, SUPPRESSION AND STEERING (VISS), Journal of intelligent material systems and structures, 7(2), 1996, pp. 241-245
AN INFORMATION-THEORY OF VISUAL COMMUNICATION
Authors: HUCK FO FALES CL RAHMAN Z
Citation: Fo. Huck et al., AN INFORMATION-THEORY OF VISUAL COMMUNICATION, Philosophical transactions-Royal Society of London. Physical sciences and engineering, 354(1716), 1996, pp. 2193-2248
IMAGE GATHERING AND DIGITAL RESTORATION
Authors: FALES CL HUCK FO ALTERGARTENBERG R RAHMAN Z
Citation: Cl. Fales et al., IMAGE GATHERING AND DIGITAL RESTORATION, Philosophical transactions-Royal Society of London. Physical sciences and engineering, 354(1716), 1996, pp. 2249-2287
RESULTS OF MDR-1 VECTOR MODIFICATION TRIAL INDICATE THAT GRANULOCYTE MACROPHAGE COLONY-FORMING UNIT CELLS DO NOT CONTRIBUTE TO POSTTRANSPLANT HEMATOPOIETIC RECOVERY FOLLOWING INTENSIVE SYSTEMIC THERAPY/
Authors: HANANIA EG GILES RE KAVANAGH J ELLERSON D ZU Z WANG T SU Y KUDELKA A RAHMAN Z HOLMES F HORTOBAGYI G CLAXTON D BACHIER C THALL P CHENG S HESTER J OSTROVE JM BIRD RE CHANG A KORBLING M SEONG D COTE R HOLZMAYER T MECHETNER E HEIMFELD S BERENSON R BURTNESS B EDWARDS C BAST R ANDREEFF M CHAMPLIN R DEISSEROTH AB
Citation: Eg. Hanania et al., RESULTS OF MDR-1 VECTOR MODIFICATION TRIAL INDICATE THAT GRANULOCYTE MACROPHAGE COLONY-FORMING UNIT CELLS DO NOT CONTRIBUTE TO POSTTRANSPLANT HEMATOPOIETIC RECOVERY FOLLOWING INTENSIVE SYSTEMIC THERAPY/, Proceedings of the National Academy of Sciences of the United Statesof America, 93(26), 1996, pp. 15346-15351
GENETIC-MODIFICATION OF CELLS USED FOR TRANSPLANT FOLLOWING INTENSIVETHERAPY FOR OVARIAN-CANCER ANP BREAST-CANCER
Authors: KAVANAGH J HANANIA E GILES R FU SQ ZU Z ELLERSON D WANG T CLAXTON D RAHMAN Z BERENSON R HEIMFELD S COTE R HOLZMAYER T MECHETNER E DAYNE A ANDREEFF M CHAMPLIN R DEISSEROTH AB
Citation: J. Kavanagh et al., GENETIC-MODIFICATION OF CELLS USED FOR TRANSPLANT FOLLOWING INTENSIVETHERAPY FOR OVARIAN-CANCER ANP BREAST-CANCER, Blood, 88(10), 1996, pp. 1075-1075
CONSOLIDATION THERAPY WITH HIGH-DOSE CYCLOPHOSPHAMIDE (HDC) REDUCES MINIMAL RESIDUAL DISEASE IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL) TREATED WITH FLUDARABINE AS INDUCTION THERAPY
Authors: WEISS M GLENN M MASLAK P RAHMAN Z MEGHERIAN L NOY A ZELENETZ A SCHEINBERG D GOLDE D
Citation: M. Weiss et al., CONSOLIDATION THERAPY WITH HIGH-DOSE CYCLOPHOSPHAMIDE (HDC) REDUCES MINIMAL RESIDUAL DISEASE IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL) TREATED WITH FLUDARABINE AS INDUCTION THERAPY, Blood, 88(10), 1996, pp. 1911-1911
MDR-1 VECTOR MARKING SHOWS THAT CFUGMS DO NOT CONTRIBUTE TO ENGRAFTMENT IN PATIENTS FOLLOWING INTENSIVE SYSTEMIC COMBINATION CHEMOTHERAPY
Authors: HANANIA E GILES R FU SQ ZU Z COTE R DAYN A WANG T ELLERSON D KAVANAGH J HOLZMAYER T MECHETNER E BERENSON R HEIMFELD S RAHMAN Z ANDREEFF M CHAMPLIN R DEISSEROTH AB
Citation: E. Hanania et al., MDR-1 VECTOR MARKING SHOWS THAT CFUGMS DO NOT CONTRIBUTE TO ENGRAFTMENT IN PATIENTS FOLLOWING INTENSIVE SYSTEMIC COMBINATION CHEMOTHERAPY, Blood, 88(10), 1996, pp. 2369-2369
Risultati: 1-25 | 26-36